If you're a hospital why would you buy any if the company was running out of cash and could go away? Now with cash and a viral platform, would hope hospitals start buying. we'll find out next qtr.
raised $20 mil, sold 40 million shares to institutional investors.@.50.someone took a HUGE position with that many shares issued
another street comment of interest:
This particular ruling (ie. the preliminary injunction), would not result in immediate
dollars to NLST. Rather, if the judge grants the injunction, we believe that Diablo
would have the right to appeal (a process that could take an additional 9 months) but
that the preliminary injunction on shipments would remain in effect unless Diablo
was able to obtain specific relief suspending that order. If not, any customers of IBM,
Huawei, and Sandisk (among others) that had received units would need to return
them and no additional shipments could be made. The brand damage that can occur
from such an action has led some companies to settle.
For a preliminary injunction to be granted, it must demonstrate 4 points, along with NLST’s claims to each point:
1) Claim is likely to succeed on its merits
a. NLST’s contract clearly stipulates that Diablo could not use the devices that it implemented using NLST’s trade secrets with disabling key functionality (specifically, load isolation and rank multiplication)
b. NLST has direct evidence that Diablo used the devices in early demos with certain customers (we believe the evidence comes from the whistleblowers and corroborated by testimony from Diablo mgmt.)
c. NLST’s expert witness demonstrates that the Diablo product stole 19 specific trade secrets (specific testimony redacted)
d. Diablo filed a patent application only a few weeks after receiving NLST confidential information, disclosing trade secrets.
2) Plaintiff would suffer irreparable harm
a. NLST cited two examples of companies who declined to work with it due to disputed IP.
b. Industry experts agree that Vault and UlltraDIMM address overlapping markets
3) The balance of equities tips in its favor, and
a. NLST claims that granting the injunction would only serve to enforce the contract as written between the two parties
4) Injunction would be in the public interest
a. Breach of confidentiality and sale of stolen technology are actions the public has an interest in stopping
Other notes from the filing of great interest to NLST investors:
• Netlist said a new Vault product to an unnamed customer (redacted) in March 2014, and expects quantities with ship with tens of thousands of units annually for the next 5 years. We believe this claim refers to its hyperscale customer, which we believe is Microsoft.
o This is consistent with our expectations in terms of units, and the commentary about expecting to generate units for 5 years provides a lot of certainty in terms of gross profit generation.
There are significant redactio
Agree with revs of $17 but if you look at net income avail to common shareholders/weighted average shares outstanding then go through the last Q (9 months income statement) you get:
to get fiscal 2014 of $1.19 (reported $1.58) excluding $2.3 mil tax benefit (.39)
Fiscal 2013 also included a $2.3m tax benefit
Q4 y/y was
$17m vs $18.3 m
Income from continuing operations $2.6m vs $2.3m
Still comes down to a real cheap stock even if you assume a flat line in eps
This morning, TEAR announced interim results of a multi-center dry eye disease (DED) prevalence study being carried out at four hospitals in the U.K.
We believe that the results of this study are extremely positive for TEAR, increasing the potential that the TearLab osmolarity test will eventually be adopted by the UK’s National Health Service (NHS).
• The study compared the effectiveness of the TearLab osmolarity test as compared to other traditional methods of diagnosing dry eye disease (DED).
• The interim results showed that of all the tests used, osmolarity had the highest correlation to actual disease
• The study also found that ‘traditional’ methods of detecting dry eye do not work well. Of particular note is the fact that ~20% of patients with significant symptoms had no other sign of dry eye except for hyperosmolarity and the fact that without an osmolarity test doctors were only able to diagnose 34 of these symptomatic patients (~28%) with dry eye disease.
• The implication from these results is that implementation of osmolarity testing could potentially improve diagnosis, and reduce cost, within the NHS. The current practice in the NHS is for symptomatic patients to visit a general practitioner, who would then refer that patient on to an ophthalmologist at a cost of approximately $60 per visit. Even then, the tests being performed by the ophthalmologist are generally ineffective. An alternative practice might be to have the GP’s accurately diagnose DED using the TEARLAB test and avoiding the ophthalmology referral altogether.
Guess you didnt realize how lumpy E&C is when you bought. Look at MTZ and MG also. Big misses, stocks get hit, then bounce back. Backlog is true indicator of whats going to happen to the stock.
Record backlog and about .05 of integration expenses in Q4. Company always gives conservative guidance at the beginning of the year.
Cant happen with Libby...anti-trust. Libby tried to buy them years ago and justice dept killed it as it would create #$%$ monopoly
its a shelf not an offering...they could say a billion shares and warrants..doesnt mean they'll issue them. You think Gary is going to severly dilute his position?
He doesnt take a job unless he's got free reign and I dont think the Clinton Group and Monomoy hired him to do anything but to fix their investment.